Romosozumab plus alendronate vs alendronate alone was associated with improved lumbar spine BMD in postmenopausal women with T2D.

A new case report was published in Oncoscience's Volume 12 on February 4, 2025, titled “Breaking point: Systemic mastocytosis manifesting as severe osteoporosis.” ...

The results offer hope for future fracture ... Jan. 22, 2025 — Following the lead of previous work on mRNA-based vaccines, therapies for spinal cord injuries and more, the method relies upon ...

Alendronate has been shown to increase bone mineral density (BMD) and decrease fracture risk in postmenopausal ... trochanter, or lumbar spine) was roughly 2%--3% greater in both alendronate ...

The FDA has approved two new biosimilars of denosumab-dssb to treat osteoporosis, increase bone mass, prevent ...